Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back

Mortality for this deadly disease has been pushed back due to therapeutic innovations. But to make further strides, new mechanisms of action and combination approaches will need to come further into play. These advances and the eventual genericization of Velcade are likely to make the regulatory and payer environment increasingly complicated.